25784-56-9

Usage

Uses

Used in Chemical Synthesis:
5-Amino-1-benzyl-1H-1,2,3-triazole-4-carboxylic acid is used as a building block for the synthesis of various complex organic molecules. Its unique structure allows it to be a versatile component in the creation of new compounds with potential applications in different fields.
Used in Research Applications:
5-Amino-1-benzyl-1H-1,2,3-triazole-4-carboxylic acid is used as a research tool in the study of organic chemistry, particularly in the exploration of new reaction pathways and the development of novel synthetic methods. Its presence in various chemical reactions can provide insights into the reactivity and behavior of similar compounds.
Used in Pharmaceutical Industry:
5-Amino-1-benzyl-1H-1,2,3-triazole-4-carboxylic acid is used as a potential precursor in the development of new pharmaceutical compounds. Its structural features may contribute to the design of drugs with specific therapeutic properties, such as antimicrobial, antiviral, or anticancer agents.
Used in Material Science:
5-Amino-1-benzyl-1H-1,2,3-triazole-4-carboxylic acid is used as a component in the development of new materials with unique properties, such as high thermal stability, chemical resistance, or specific optical characteristics. Its incorporation into material formulations can lead to the creation of advanced materials for various applications, including electronics, aerospace, and automotive industries.

InChI:InChI=1/C10H10N4O2/c11-9-8(10(15)16)12-13-14(9)6-7-4-2-1-3-5-7/h1-5H,6,11H2,(H,15,16)

Upstream product

• 372-09-8 cyanoacetic acid 
• 622-79-7 benzyl azide 

Downstream Products

• 25784-58-1 1-benzyl-1H-1,2,3-triazol-5-amine 
• 1611444-77-9 3-{2-[(1-benzyl-1H-1,2,3-triazol-5-yl)amino]-5-chlorophenyl}-2,2-dimethylpropanoic acid 
• 1611444-58-6 [2-[(3-benzyltriazol-4-yl)amino]-5-chlorophenyl]methanol 
• 1648842-50-5 2-((1-benzyl-1H-1,2,3-triazol-5-yl)amino)-5-chlorobenzoic acid 
• 1611444-60-0 2-[(3-benzyltriazol-4-yl)amino]-5-chlorobenzonitrile 
• 1611444-59-7 N-[2-(aminomethyl)-4-chlorophenyl]-3-benzyltriazol-4-amine 
• 1611444-61-1 N-[[2-[(3-benzyltriazol-4-yl)amino]-5-chlorophenyl]methyl]acetamide 
• 1611444-62-2 1-benzyl-N-(4-fluoro-2-methylphenyl)-1H-1,2,3-triazol-5-amine 
• 1611444-75-7 3-(2-((1-benzyl-1H-1,2,3-triazol-5-yl)amino)-5-chlorobenzylidene)cyclobutanecarboxylic acid 

Relevant academic research and scientific papers

Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones

The present invention relates to novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones, pharmaceutical compositions containing such compounds the use of such compounds to treat neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.

2,3 Disubstituted- (5,6)-heteroarylfused-pyrimidine-4-ones

The present invention relates to novel compounds of the formula I, described above, and their pharmaceutically acceptable salts, and pharmaceutical compositions and methods of treating neurodegenerative and CNS-trauma related conditions.

Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones

From EXEMP_CLAIMS : 1. A bicyclic compound of the formula wherein ring positions ""F"" and ""G"" may be independently selected from carbon, nitrogen, oxygen or sulfur, and J is independently selected from carbon, nitrogen or oxygen with the proviso that: i) if more than two of ""F"", ""G"" or ""J"" is a heteroatom then said 5 membered heteroaromatic ring is selected from the group consisting of (1,2,3)-triazole, (1,2,3)-thiadiazole, (1,2,5)-thiadiazole, and (1,2,5)-oxadiazole; and ii) if two of ""F"", ""G"" or ""J"" are heteroatoms, one of said heteroatoms may be oxygen or sulfur; wherein said fused heteroaromatic rings may optionally be independently substituted on any of the carbon or nitrogen atoms capable of forming an additional bond with a substituent selected from hydrogen, (C1-C6)alkyl, halogen, trifluoromethyl, amino-(CH2)n-, (C1-C6)alkylamino-(CH2)p-, di(C1-C6)alkyl-amino-(CH2)n-, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkyl-O-(C1-C6)alkyl-, -CN, hydroxy,-NO2, R3-C(=O)-, R4-O-C(=O)-, di(C1-C6)alkyl-N-C(=O)-, (C1-C6)cycloalkyl, and R4-NH-C(=O)-, and phenyl optionally substituted with halo, (C1-C6) alkyl, -CN, or -CF3; R1 is substituted phenyl of the formula Ph1 or heteroaryl wherein said heteroaryl is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, wherein said heteroaryl may optionally be substituted on any of the atoms capable of forming an additional bond, up to a maximum of three substituents, with a substituent selected from hydrogen, (C1-C6)alkyl, halogen, trifluoromethyl, amino-(CH2)n-, (C1-C6)alkylamino-(CH2)n-, di(C1-C6)alkyl-amino-(CH2)n-, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkyl-O-(C1-C6)alkyl-, -CN, hydroxy, H-C(=O)-, (C1-C6)alkyl-C(=O)-, HO-C(=O)-, (C1-C6)alkyl-O-C(=O)-, NH2-C(=O)-, (C1-C6)alkyl-NH-C(=O)-, (=O)-, and di(C1-C6)alkyl-NH-C(=O)-; wherein said Ph1 is a group of the formula R2 is disubstituted phenyl of the formula Ph2 or a five or six membered heterocycle, wherein said 6-membered heterocycle has the formula wherein ""N"" is nitrogen; wherein said ring positions ""K"", ""L"" and ""M"" may be independently selected from carbon or nitrogen, with the proviso that only one of ""K"", ""L"" or ""M"" can be nitrogen; wherein said five membered heterocycle has the formula wherein said ring positions ""P,"" ""Q"" and ""T"" may be independently selected from carbon, nitrogen, oxygen or sulfur; with the proviso that only one of ""P,"" ""Q"" or T can be oxygen or sulfur and at least one of ""P,"" ""Q"" or ""T"" must be a heteroatom; wherein said Ph2 is a disubstituted group of the formula R3 is hydrogen or (C1-C6) alkyl; R4 is hydrogen or (C1-C6) alkyl; R5 is hydrogen (C1-C6)alkyl, halo, CF3, (C1-C6)alkoxy or (C1-C6)alkylthiol; R6 is hydrogen or halo; R7 is hydrogen or halo; R8 is hydrogen or halo; R9 is hydrogen, (C1-C6)alkyl optionally substituted with one to three halogen atoms, halo, CF3, [C1-C6)alkoxy optionally substituted with one to three halogen atoms, (C1-C6)alkylthiol, R13O-(CH2)p-, (C1-C6)alkyl-NH-(CH2)p-, di(C1-C6)alkyl-N-(CH2)n-, (C1-C5)cycloalkyl-NH-(CH2)p-, H2N-(C=O)-(CH2)p-, (C1-C6)alkyl-HN-(C=O)-(CH2)p-, di(C1-C6)alkyl-N-(C=O)-(CH2)p-, (C1-C5)cycloalkyl-NH-(C=O)-(CH2)p-R13O-(C=O)-(CH2)p-(C1-C6)alkyl-(O=C)-O-(C1-C6)-alkyl-, (C1-C6)alkyl-O-(O=C)-O-(C1-C6)-alkyl-, (C1-C6)alkyl(O=C)-O-, (C1-C6)alkyl-(O=C)-NH-(CH2)p-, H(O=C)-NH-(CH2)p-, hydroxy, H-C(=O)-(CH2)p-, (C1-C6)alkyl-C(=O)-, (C1-C6)alkyl-O-C(=O)-, R4-(CH2)p-O-C(=O)-, amino-(CH2)p-, hydroxy-(C1-C6)alkyl-, (C1-C6)alkyl-O-(C1-C6)alkyl-, and -CN; R10 and R14 are hydrogen, (C1-C6)alkyl optionally substituted with one to three halogen atoms, halo, CF3, (C1-C6)alkoxy optionally substituted with one to three halogen atoms, (C1-C6)alkyl-NH-(CH2)p-, (C1-C6)alkyl-NH-(CH2)p-, di(C1-C6)alkyl-N-(CH2)p-, (C1-C5)cycloalkyl-NH-(CH2)p-, H2N-(C=O)-(CH2)p-, (C1-C6)alkyl-HN-(C=O)-(CH2)p-, di(C1-C6)alkyl-N-(C=O)-(CH2)p-, (C1-C5)cycloalkyl-NH-(C=O)-(CH2)p-, R13O-(C=O)-(CH2)p-, (C1-C6)alkyl-(O=C)-O-(C1-C6)alkyl-, (C1-C6)alkyl-O-(O=C)-O-(C1-C6)-alkyl-, (C1-C6)alkyl-(O=C)-O-, (C1-C6)alkyl-(O=C)-NH-(CH2)p-, H(O=C)-NH-(CH2)p-, hydroxy, H-C(=O)-(CH2)p-, (C1-C6)alkyl-C(=O)-, (C1-C6)alkyl-O-C(=O)-, R4-(CH2)p-O-C(=O)-, amino-(CH2)p-, hydroxy-(C1-C6)alkyl, (C1-C6)alkyl-O-(C1-C6)alkyl. -CHO and -CN; R11 is hydrogen or halo; R12 is hydrogen or halo; R13 is hydrogen, (C1-C6)alkyl, (C1-C6)alkyl-(C=O)-, (C1-C6)alkyl-O-(C=O)-, (C1-C6)alkyl-O-(C=O)-, or di(C1-C6)alkyl-N-(C=O)-; R15 is hydrogen, -CN, (C1-C6) alkyl, halo, CF3, -CHO or (C1-C6)alkoxy; R16 is hydrogen, -CN, (C1-C6)alkyl, halo, CF3, -CHO or (C1-C6)alkoxy; R17 is hydrogen, -CN, (C1-C6)alkyl, halo, CF3, CHO or (C1-C6)alkoxy; n is an integer from zero to 3; p is an integer from zero to 3; wherein the dashed bond represented an optional double bond; with the proviso that when R9 is hydrogen, then one of R11 and R12 is other than hydrogen; and the pharmaceutically acceptable salts of such compounds.